Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

This study tests a four-drug combination — gemcitabine, cisplatin (chemotherapy), lenvatinib (a targeted drug), and adebrelimab (an immunotherapy) — for people with advanced bile duct cancer starting inside the liver (intrahepatic cholangiocarcinoma) that cannot be surgically removed. **You may be eligible if...** - You are 18–75 years old with a confirmed diagnosis of advanced, unresectable intrahepatic cholangiocarcinoma - You have good liver function (Child-Pugh A) and adequate organ function overall - You have at least one measurable tumor on scans - You have a life expectancy of at least 12 weeks - You are not pregnant or breastfeeding **You may NOT be eligible if...** - You have been previously treated with PD-1, PD-L1, or CTLA-4 immunotherapy - Your cancer includes liver cancer (hepatocellular carcinoma) or other non-bile duct tumor types - You have another active cancer - Your organ function does not meet the required minimums Talk to your doctor to see if this trial is right for you.